Demystifying Wound Care Excellence: Unlocking the Secrets to Transformational Healing

Randall Spencer, Vice President of Clinical Innovations Mr. Spencer is the co-founder of Surgical Biologics, a leading processor of amnion tissue for use in a variety of surgical implants. Since the founding of Surgical Biologics in 2006, he led the development of the proprietary PURION® process, which processes human amniotic membrane to produce a safe, effective and minimally manipulated implant for homologous use. He has been a pioneer in the development of the latest advances in processing amniotic membrane tissue. MIMEDX® acquired Surgical Biologics in January 2011, and Mr. Spencer currently serves as Vice President of Clinical Innovation

Kathleen has recently celebrated her 54th year of working in the medical reimbursement arena. As the founder and president of her own consulting company, Kathleen D. Schaum & Associates, Inc. she shares her 50+ years of knowledge and experience with wound/ulcer management stakeholders.

Dr. Frank H. Lau is a board-certified plastic and reconstructive surgeon with extensive expertise in regenerative medicine, wound healing, and clinical research. He completed his surgical training at the Harvard Combined Plastic Surgery Program and a research fellowship at Massachusetts General Hospital’s Simches Center for Regenerative Medicine. Dr. Lau is internationally recognized for his contributions to limb salvage, having developed a novel, tissue-engineered approach utilizing dehydrated human amniotic/chorionic membrane. His work includes a landmark randomized controlled trial comparing regenerative and flap-based reconstruction, which has informed clinical practice and earned national recognition. He has received numerous accolades, including the Best Paper Award from the American College of Surgeons for his cost-effectiveness analysis of regenerative limb salvage. As Principal Investigator of the Lau Tissue Engineering Lab, he led over 20 funded clinical and translational studies in surgical innovation. Dr. Lau has published widely in peer-reviewed journals, and lectures frequently on advancements in complex wound care and reconstructive strategies. 

Ms. Massee has over 15 years of experience in R&D with a focus in regenerative medicine. She studied Biomedical Engineering at the Georgia Institute of Technology and has been with MIMEDX since 2010. During her tenure, she has published numerous articles in peer-reviewed journals to advance our understanding of placental-based technologies. Under her leadership, the company has also continued to expand their portfolio through the development of innovative solutions for advanced wound healing.

Dr. John Harper joined MIMEDX as Chief Science Officer and Senior Vice President of Research and Product Development in June 2021. Dr. Harper has over 40 peer-reviewed publications and his principal areas of research interest are extracellular matrix biochemistry, tissue regeneration, and wound healing. He received his Ph.D. in Biomedical Sciences from The University of Texas, M.D. Anderson Cancer Center in Houston and completed post-doctoral fellowships in cancer biochemistry and cell biology at Scripps Clinic in La Jolla, California and the National Cancer Institute in Bethesda, Maryland.

Dr. Harper serves on the Board of Directors of Kent Imaging, Nanomedic Technologies, and the American College of Wound Healing and Tissue Repair.

Dr. Scott Boynton, DPM., is an Assistant Professor of Surgery within the Division of Vascular Surgery at Oregon Health & Science University in Portland, Oregon.

He completed his residency at UCLA and comes to OHSU after 10 years of academic practice at the UCLA Gonda Vascular Center. He is an active researcher with multiple funded clinical trials over the past decade and plays a key role in OHSU's life-saving multidisciplinary functional limb preservation program.